SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001157523-23-001700
Filing Date
2023-11-09
Accepted
2023-11-09 08:00:41
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 EDGEWISE THERAPEUTICS, INC. 8-K a53795839.htm   iXBRL 8-K 29680
2 EXHIBIT 99.1 a53795839ex99_1.htm EX-99.1 60684
  Complete submission text file 0001157523-23-001700.txt   271819

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20231109.xsd EX-101.SCH 4083
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ewtx-20231109_def.xml EX-101.DEF 17549
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20231109_lab.xml EX-101.LAB 26909
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20231109_pre.xml EX-101.PRE 19749
8 EXTRACTED XBRL INSTANCE DOCUMENT a53795839_htm.xml XML 4220
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

IRS No.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 231390134
SIC: 2834 Pharmaceutical Preparations